corp_html/html/Pipeline-2.htm

<p><b>NCEs in Development Phase</b></p>
<p><b>PLD-116</b></p>
<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase 
  I clinical study in Germany in December 2000. Prior to that, all the activities 
  necessary to fulfill the requirements for the clinical testing of the compound 
  had been undertaken and the pre-clinical testing completed. The PLD-116 project 
  team has been established in December 1999, to develop peptide PL-10.1 into 
  a drug for the treatment of inflammatory bowel disease.</p>
<p><b>PLD-117</b></p>
<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication 
  of cancer chemotherapy, was brought to clinical study trials in the USA in December 
  2000. The proposed treatment is based on a unique approach using peptide that 
  activates thrombopoietin (TPO) receptor. Prior to favourable communication from 
  the FDA regarding the IND filling, and the evaluation of the clinical protocol, 
  PLIVA has signed a licensing agreement with Receptron, Inc., a Californian based 
  Biotech Company, and acquired exclusive rights to develop and market this possible 
  new drug.</p>
<p><b>PLD-118</b></p>
<p>The licensed in novel antifungal agent PLD-118 was successfully brought into 
  clinical development ahead of schedule in November 2000. PLD-118 has the potential 
  to be the first novel oral antifungal for the treatment of Candida infections 
  since the introduction of azoles in the 80's. After completing the preclinical 
  package and successful review of necessary documents by the ethics committee 
  in Germany, clinical studies started in November. According to the planned time 
  schedule, multiple dosing will be finished in May 2001, while the project team 
  will have already begun the proof of concept study, which is anticipated to 
  start in third quarter of 2001.</p>
1	<p><b>NCEs in Development Phase</b></p>
2	<p><b>PLD-116</b></p>
3	<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase
4	I clinical study in Germany in December 2000. Prior to that, all the activities
5	necessary to fulfill the requirements for the clinical testing of the compound
6	had been undertaken and the pre-clinical testing completed. The PLD-116 project
7	team has been established in December 1999, to develop peptide PL-10.1 into
8	a drug for the treatment of inflammatory bowel disease.</p>
9	<p><b>PLD-117</b></p>
10	<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication
11	of cancer chemotherapy, was brought to clinical study trials in the USA in December
12	2000. The proposed treatment is based on a unique approach using peptide that
13	activates thrombopoietin (TPO) receptor. Prior to favourable communication from
14	the FDA regarding the IND filling, and the evaluation of the clinical protocol,
15	PLIVA has signed a licensing agreement with Receptron, Inc., a Californian based
16	Biotech Company, and acquired exclusive rights to develop and market this possible
17	new drug.</p>
18	<p><b>PLD-118</b></p>
19	<p>The licensed in novel antifungal agent PLD-118 was successfully brought into
20	clinical development ahead of schedule in November 2000. PLD-118 has the potential
21	to be the first novel oral antifungal for the treatment of Candida infections
22	since the introduction of azoles in the 80's. After completing the preclinical
23	package and successful review of necessary documents by the ethics committee
24	in Germany, clinical studies started in November. According to the planned time
25	schedule, multiple dosing will be finished in May 2001, while the project team
26	will have already begun the proof of concept study, which is anticipated to
27	start in third quarter of 2001.</p>